This is a standard inducement grant for a new hire and should not be interpreted as a strategic or financial signal. Traders should monitor upcoming clinical trial updates for ORIC-944 and enozertinib as the primary value drivers.
ORIC drugs
ORIC drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $8.91entry
- T+1 · 7mo ago −0.45%α −0.51% · $8.87
- T+5 · 7mo ago +16.72%α +12.59% · $10.40
- T+20 · 7mo ago +8.08%α −0.90% · $9.63
- T+60 · 5mo ago +22.22%α +8.75% · $10.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ORIC Pharmaceuticals announced the grant of stock options and restricted stock units to a new non-executive employee as an inducement to employment, approved under Nasdaq Rule 5635(c)(4). The move is a routine hiring incentive and does not reflect a material change in the company's operations or financial condition.
Key Facts
- ORIC granted 80,000 non-qualified stock options and 15,000 restricted stock units to a new non-executive employee.
- Grants were made on April 1, 2026, under the 2022 Inducement Equity Incentive Plan.
- Stock options vest 25% after one year, with the remainder vesting monthly over 36 months; RSUs vest in thirds over three years.
- The Compensation Committee approved the grants in accordance with Nasdaq rules for inducement awards.
Financial Impact
Minimal near-term financial impact; total equity grant of 95,000 shares represents less than 0.1% of outstanding shares (based on $892M market cap).
Risk Factors
- Potential for minor shareholder dilution over time as equity vests.
- Forward-looking statements in the release carry standard biotech development risks, including clinical trial failure and funding needs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268139 |
Track record
12 reports on ORIC
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Press Release Neutral 5/10 Entry $7.52 Now $7.52 −0.00% settles Nov 24
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $7.59 Now $7.52 −0.92% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.72 Now $7.52 −2.59% settles Nov 23
- Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $8.91 Now $7.52 −15.60% settles Nov 17
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $13.17 to $9.24 Now $7.52 −42.90% ▼ −29.84% −29.28% vs SPY
- Oct 5, 20266w ago Press Release Bullish 6/10 Entry $11.98 to $11.31 Now $7.52 −37.23% ▼ −5.59% −5.45% vs SPY
- Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $12.49 to $11.81 Now $7.52 −39.79% ▼ −5.44% −5.87% vs SPY
- Aug 3, 202615w ago Press Release Neutral 5/10 Entry $13.47 to $13.73 Now $7.52 −44.17% ▲ +1.93% +2.03% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.91 to $10.16 Now $7.52 −15.60% ▲ +13.97% +12.96% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $7.82 to $8.63 Now $7.52 −3.84% ▲ +10.36% +9.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers